BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18199612)

  • 1. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
    Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
    Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
    Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
    AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
    Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
    Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.
    Grigsby PW; Malyapa RS; Higashikubo R; Schwarz JK; Welch MJ; Huettner PC; Dehdashti F
    Mol Imaging Biol; 2007; 9(5):278-83. PubMed ID: 17431727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
    Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
    Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
    Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
    Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
    J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
    Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
    Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of
    Toriihara A; Ohtake M; Tateishi K; Hino-Shishikura A; Yoneyama T; Kitazume Y; Inoue T; Kawahara N; Tateishi U
    Ann Nucl Med; 2018 May; 32(4):264-271. PubMed ID: 29453680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.
    Burgman P; O'Donoghue JA; Lewis JS; Welch MJ; Humm JL; Ling CC
    Nucl Med Biol; 2005 Aug; 32(6):623-30. PubMed ID: 16026709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
    Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
    Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F]fluorodeoxyglucose and L-methyl-[(11)C]methionine PET.
    Tateishi K; Tateishi U; Nakanowatari S; Ohtake M; Minamimoto R; Suenaga J; Murata H; Kubota K; Inoue T; Kawahara N
    AJNR Am J Neuroradiol; 2014 Feb; 35(2):278-84. PubMed ID: 23928140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
    Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
    Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
    Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.